SOLID TUMORS

This study tests a new drug, BI 3923948, in people with advanced solid tumors that have spread and are hard to treat. About 60 adults will receive the drug alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it shrinks tumors. The drug is inje…

This early-stage study tests a new drug, INCB161734, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with other cancer treatments. About 710 adults whos…

This early-phase study tests a new drug called INCB123667, given alone or with other cancer therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor …

This early-phase study tests a radioactive drug called lutetium [177Lu] BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Participants must have meas…

This early-stage study tests a new drug, QTX3034, in 250 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with another drug called cetuximab. Participants m…

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 40 adults who have already tried st…

This early-stage study is testing a new drug called HDM2017 in 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Researchers will also look at how the drug moves through the bod…

This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The therapy uses a patient's own immune cells, modified to target a protein (B7-H3) on cancer cells. The main goals are to ch…

This early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer dru…

This study tests an experimental drug called JAB-30355 in adults with advanced solid tumors that have a specific mutation in the TP53 gene (Y220C). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 144 participants who have already tried at least one…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then, refining the dose; and finally, checking how well the drug shrinks tumors. All participants receive the …

This study looks at the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in people with solid tumors or blood cancers. Participants are already receiving or have received pembrolizumab in earlier studies and will continue treatment or follow-up for u…

This study tests a drug called FORE8394 (plixorafenib) in people with advanced solid tumors or brain tumors that have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants aged 10 and older will take the pill and…

This study looks at gene changes (mutations) in cancer cells from people with solid tumors or blood cancers. Researchers use leftover tumor tissue from past surgeries or biopsies, plus a blood or saliva sample, to find mutations that might affect how a cancer responds to treatmen…